406 results on '"Wheatley-Price, Paul"'
Search Results
2. Oral targeted therapy for the treatment of non-small cell lung carcinoma
3. Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial
4. ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results
5. Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2− Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial
6. Real-World Immunotherapy Use and Effectiveness in Advanced NSCLC With Programmed Death-Ligand 1 Greater Than or Equal to 50% and Greater Than or Equal to 90%
7. A biomarker-directed, multi-center phase II/III study of ctDNA molecular response adaptive immuno-chemotherapy in patients with non-small cell lung cancer.
8. Clinicopathological features of pulmonary mucinous adenocarcinoma: A descriptive analysis
9. What Is Ailing Oncology Clinical Trials? Can We Fix Them?
10. The importance of greater speed in drug development for advanced malignancies
11. Involvement of Palliative Care in Malignant Pleural Mesothelioma Patients and Associations with Survival and End-of-Life Outcomes
12. The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer
13. Three Decades of Malignant Pleural Mesothelioma: An Academic Center Experience
14. New Anticancer Drugs: Reliably Assessing "Value" While Addressing High Prices.
15. Applicability of the PACIFIC trial results in patients not eligible for the PACIFIC trial: Canadian rapid consensus statement and recommendations.
16. Real-world immunotherapy usage and effectiveness in advanced PD-L1 ≥50% and PD-L1 ≥90% non-small cell lung cancer
17. A brief history of lung cancer in Canada: Care, contributions and challenges
18. Treatment patterns and outcomes in KRASG12C‐positive advanced NSCLC patients previously treated with immune checkpoint inhibitors: A Canada-wide real-world, multi-center, retrospective cohort study
19. Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Patients With Previously Untreated Advanced Non–Small-Cell Lung Cancer
20. Inpatients versus outpatients with advanced non-small cell lung cancer: Characteristics and outcomes
21. What Attributes Matter Most in Physicians? Exploratory Findings from a Single-Centre Survey of Stakeholder Priorities in Cancer Care at a Canadian Academic Cancer Centre
22. The utility of H2 receptor antagonists in preventing infusion‐related reactions to paclitaxel chemotherapy
23. 218 Management of Very Early Small Cell Lung Cancer: A Canadian Survey Study
24. Medical Assistance in Dying in Patients With Cancer
25. Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC
26. Radical Treatment of Stage II Non–small-cell Lung Cancer With Nonsurgical Approaches: A Multi-institution Report of Outcomes
27. The Impact of Baseline Edmonton Symptom Assessment Scale Scores on Treatment and Survival in Patients With Advanced Non–small-cell Lung Cancer
28. A prospective intervention to improve happiness and reduce burnout in oncologists
29. Canadian Consensus Recommendations on the Management of Extensive-Stage Small-Cell Lung Cancer
30. Management of Very Early Small Cell Lung Cancer: A Canadian Survey Study
31. Abstract CT212: A ctDNA-directed, multi-center phase II study of molecular response adaptive immuno-chemotherapy in patients with non-small cell lung cancer: Analysis of Stage 1 of CCTG BR.36
32. A rare case of false negative ROS1 fusion in metastatic pulmonary adenocarcinoma: Case report and lessons learned
33. The influence of season and distance to a cancer centre on lung cancer treatment rates
34. Follow-Up Imaging Guidelines for Patients with Stage III Unresectable NSCLC: Recommendations Based on the PACIFIC Trial
35. Brief Report: Canadian Cancer Trials Group IND.227: A Phase II randomized study of pembrolizumab in patients with advanced malignant pleural mesothelioma (NCT02784171).
36. Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial
37. Patients With Advanced Non–Small Cell Lung Cancer Requiring Inpatient Medical Oncology Consultation: Characteristics, Referral Patterns, and Outcomes
38. Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience.
39. Chemotherapy in the oldest old: The feasibility of delivering cytotoxic therapy to patients 80 years old and older
40. Stereotactic Body Radiotherapy (SBRT) in Very Limited-Stage Small Cell Lung Cancer (VLS-SCLC)
41. Access to Cancer Drugs in Canada
42. Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171)
43. Chemotherapy in the Elderly: Standard Chemotherapy or Specific Regimens?
44. 182: Staff Stress at a Canadian Cancer Centre
45. 184: Staff Satisfaction at a Canadian Cancer Centre
46. Epidermal Growth Factor Receptor Inhibitors in the Treatment of Non-small Cell Lung Cancer
47. Prognostic Factors in the Radical Nonsurgical Treatment of Stage IIIB Non–Small-Cell Lung Cancer
48. Thymic Epithelial Neoplasms: A 12-Year Canadian Regional Cancer Program Experience
49. Third-Line Chemotherapy in Small-Cell Lung Cancer: An International Analysis
50. Insights into the advanced non-small cell lung cancer patient journey: Treatment decision-making, preferences, and quality of life considerations.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.